Design and activity evaluation of new EGFR tyrosine kinase inhibitors containing cyclic polyamines

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• The epidermal growth factor receptor (EGFR) tyrosine kinase (TK) pathway is a key target in non-small-cell lung cancer (NSCLC).
• Developing effective EGFR inhibitors against wild-type and resistant mutant forms remains a critical challenge in NSCLC treatment.
• ATP-competitive inhibitors targeting EGFR are essential for NSCLC therapy.

Purpose of the Study:

• To design and synthesize novel quinazoline-based compounds incorporating macrocyclic polyamines.
• To enhance inhibitory activity against drug-resistant non-small-cell lung cancer (NSCLC) cells, particularly those with EGFR mutations.
• To evaluate the efficacy of these derivatives as potential EGFR inhibitors.

Main Methods:

• Synthesis of Erlotinib and Icotinib derivatives with a macrocyclic polyamine moiety.
• Assessment of inhibitory activity against EGFR-mutated cancer cell lines.
• Determination of half-maximal inhibitory concentration (IC50) values for key compounds.

Main Results:

• Several novel derivatives were synthesized and tested for EGFR inhibitory potential.
• Compounds showed modest activity against EGFR triple mutants (EGFR^{del19/T790M/C797S}).
• Compound b exhibited a specific IC50 of 496.3 nM against PC-9^{del19/T790M/C797S} cells.

Conclusions:

• The developed compounds offer a starting point for optimizing EGFR inhibitors.
• Incorporating macrocyclic polyamines may aid in overcoming resistance mechanisms in NSCLC.
• Further research is warranted to improve efficacy against challenging EGFR triple mutations.